Drug Related Thyroid Myopathy: Hoffmann's Syndrome Case Report/Ilac Iliskili Tiroid Miyopati: Hoffmann Sendromu Olgu Sunumu

Hypothyroid myopathy is a muscle disease with endocrine disease related abnormal hormone levels and Hoffman's syndrome is a rare form of hypothyroid myopathy. The disease commonly involves muscle weakness, muscle pain, and cramps. In this case, we talked about the clinical and laboratory findin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Boğaziçi tıp dergisi 2022-12, Vol.9 (4), p.276
Hauptverfasser: Turkok, Cansu Gulcihan, Aksahin, Okan, Dogan, Ceyda, Senol, Mehmet Guney, Ozdag, Mehmet Fatih
Format: Artikel
Sprache:tur
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hypothyroid myopathy is a muscle disease with endocrine disease related abnormal hormone levels and Hoffman's syndrome is a rare form of hypothyroid myopathy. The disease commonly involves muscle weakness, muscle pain, and cramps. In this case, we talked about the clinical and laboratory findings and his good response to hormone replacement therapy of a patient with Hoffmann syndrome who developed due to hypothyroidism myopathy. A 22-year-old male patient, diagnosed with graves 2 years ago, after that he had a bilateral thyroidectomy surgery 1.5 years ago, has been still using L-thyroxine 150 mcg/day. In the patient's history, it was learned that intramuscular hormone therapy was administered to his 2 months ago for bodybuilding purposes without the doctor's advice. When he applied to us, he was suffering from widespread muscle cramps, muscle pain, and weakness for 1 month. It is learned that he had methyltestosterone injection 2 months ago and after 3 weeks of injections, symptoms had been showed up. In laboratory findings, while sT3, sT4 levels were low, TSH and CK levels were high. On examinations, muscle hypertrophy was more specifically seen on proximal muscles. He is diagnosed with Hoffmann's Syndrome and L thyroxine treatment has rearranged from 150 mcg/day to 250 mcg/day. During the follow-up of the patient, complete improvement was observed in the clinical and laboratory findings and the follow-up, and treatment continues.
ISSN:2149-0287
2149-0287
DOI:10.14744/bmj.2022.09226